Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BIOCON Limited is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters involves 4 distinct examiners across 3 distinct art units. This distribution indicates that the portfolio faces a variety of examiner viewpoints while maintaining some overlap in art unit oversight. The presence of 4 distinct examiners for the 4 pending office actions means that each active case is being reviewed by a different individual.
The busiest examiner in this portfolio is HIBBERT, CATHERINE S, who is responsible for 1 pending office action. Since there are 4 pending office actions in total, the workload is distributed among the 4 distinct examiners. This lack of concentration means that no single examiner dominates the current prosecution landscape for the company. With 3 distinct art units involved, the company must navigate the specific nuances of multiple technical divisions within the Biotechnology & Pharmaceuticals area. The strategy requires managing separate examiner dockets simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 88.7% | +10.2% |
| GEORGE, DENNIS CHERIAN | 1 | 38.5% | +72.7% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682254 | PURIFICATION OF LIRAGLUTIDE | HIBBERT, CATHERINE S | — |
| 18283281 | PROCESS FOR PREPARATION OF CABOZANTINIB | SANCHEZ, JUSTIN CHRISTOPHER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682254 | PURIFICATION OF LIRAGLUTIDE | HIBBERT, CATHERINE S | — |
| 18283281 | PROCESS FOR PREPARATION OF CABOZANTINIB | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18335542 | USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6 | GEORGE, DENNIS CHERIAN | — |
| 18199675 | FORMULATIONS OF ANTIBODY | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1644 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682254 | PURIFICATION OF LIRAGLUTIDE | HIBBERT, CATHERINE S | — | §103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18283281 | PROCESS FOR PREPARATION OF CABOZANTINIB | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18335542 | USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6 | GEORGE, DENNIS CHERIAN | 1644 | §103§112DP | Final Rejection | — | Pending | Jun 15, 2023 |
| 18199675 | FORMULATIONS OF ANTIBODY | KIM, YUNSOO | 1641 | §112Other | Final Rejection | — | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial